Pod Insights a16z Podcast a16z Podcast: The Biology of Pain About this episode What is the nature of physical pain? Why do we even experience it? Is there one type, or many? Do people experience pain differently? What is happening in our brains and our bodies when we experience pain? What is the biological link between pain ...
Transcript Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.
0:00 Hanne Tidnam? Hi and welcome to the A16Z Podcast. I'm Hannah. In this episode, we talk all about the biology of pain with Clifford Wolf, Professor of Neurobiology at Harvard Medical School, who has dedicated his career to the subject. The conversation covers everything you ever wondered about the nature of pain, from why we even feel it and what the biological purpose of pain is, to whether or not all pain is the same, or if some kinds of pain function differently, feel different, have different purposes, or even if some people feel pain differently from others. Wolf describes the four different broad types of pain we experience, what the purpose of each one is, what it means now that we can phenotype different kinds of pain and begin to understand them as distinct and different from each other,
0:43 Hanne Tidnam? and how technology is enabling this new, deeper, and much more complex understanding of the nature of pain. We also talk about what the biological link between pain and addiction really is, plus the one thing you might do that we know makes your experience of pain worse. You've been working on the subject of pain for your entire career. What drew you to that subject to begin with? What was it that first sparked that initial interest for you and where you began investigating?
1:09 Speaker 01 When I was a medical student, I was on the surgical ward. And at that time, there was minimal treatment for post-operative pain. So I came into the ward and there were a group of patients who had had major surgery. And all of them were in severe discomfort. And I said to the attending surgeon, "What are you doing? Why aren't you treating them with pain?" And he looked at me as if I was crazy and he said, "They've just had surgery. What do you expect? They're in pain."
1:38 Hanne Tidnam? Even the idea of treating the pain was not...
1:41 Speaker 01 Absolutely. It was just thought, you have surgery, you have pain, and then you put up with it until the pain goes. And I just thought to myself, "That doesn't sound right." At that time, there was very little understanding of the mechanisms of pain, and indeed, very few treatment options. Now, as we have... Much greater understanding, but unfortunately, the treatment options haven't really expanded. And they are also accompanied by undesired effects, particularly in the case of the opioids.
2:10 Hanne Tidnam? So let's talk a little bit about what the understanding looked like then and what it's beginning to look like now. So what was our understanding of the mechanism of pain back then, when we just sort of assumed, okay, you have surgery, you're in pain?
2:22 Speaker 01 At that time, I just thought that all pain is similar, that you either have no pain or you have pain. And if you have pain, it's an unpleasant sensation. The closest analogy, it would be like flicking a switch that switched on the pain sensation in your, in your brain.
2:38 Hanne Tidnam? So we thought it was that simple.
2:39 Speaker 01 We thought there was a peripheral trigger, which could be mild, like a pinprick or touching something too hot or too cold, or larger in the, in the sense of major trauma or post-surgical. There was something that was activating the, the pain switch and that all the triggers of pain acted on a single system in a single way. And therefore, pain really was not present or mild, moderate or severe. And that was the full range of the understanding of pain.
3:08 Hanne Tidnam? Describe a little bit what the thought was around that system, like how would that system be activated? Or how would, what was our understanding of that system?
3:15 Speaker 01 Well, it certainly was appreciated that pain has two facets. One, it is an essential early warning device. It, it tells us of danger in the environment. And without it, there's a high risk that we may injure ourselves. So you need this alarm system, if you like.
3:34 Hanne Tidnam? And in the case of surgery, that alarm system is going because you're vulnerable, you're exposed, you're healing.
3:39 Speaker 01 The alarm system is activated by the surgeon's damage that is created in, in the patient. And then the alarm system continues until that, that tissue injury is repaired. But what is happening in a patient who has persistent pain for years and years and years? Why is that pain alarm activated continuously? And there really was no explanation at the time.
4:01 Hanne Tidnam? So that's where you began your research?
4:04 Speaker 01 Exactly. And at that time, if you had mild pain, then you took a non-steroidal anti-inflammatory drug like Tylenol or Advil. If you had more severe pain, you added a weak opioid to your NSAID. And if you had severe pain, then that's the point at which you'd give a stronger opioid. And the World Health Organization had an analgesic ladder that it literally was that mild, moderate, severe pain, increasing the strength of the analgesic. And again, in keeping with this notion that pain was a unitary system activated by different triggers of different intensity.
4:38 Hanne Tidnam? It's so simple. It makes me think of the signs in the nurses' doctor's office with the smiling faces. Like even that is a whole order of magnitude above in terms of understanding.
4:47 Speaker 01 Unfortunately, the reality is those smiley faces would not be smiling if they saw how complicated pain was. The notion that there's a simple switch is just incorrect. The notion that pain can be defined by its severity as mild, moderate, or severe is incorrect. And the notion that the treatment should be based on that is also incorrect.
5:09 Hanne Tidnam? What is it that has shifted in our understanding of the biology of how much more complex it is?
5:14 Speaker 01 Pain as an early warning device, a kind of radar for danger, if you like, is completely different from the pain that occurs in the setting of a patient who has persistent pain.
5:26 Hanne Tidnam? The quality of the pain?
5:27 Speaker 01 No, that was the confusing element.
5:29 Hanne Tidnam? Yeah.
5:30 Speaker 01 We use the same word, pain, to describe both, and therefore physicians and patients felt this is the same phenomenon. But in fact, the pain that we experience does not reflect what is initiating and sustaining the pain. In the case of a pain as a protective mechanism, you need just an intense stimulus, one of sufficient intensity that potentially can damage our tissues. And we have this very elaborate system that has been designed to detect that danger. So we have specialized sensory neurons that are activated only by intense stimuli. And when they reach that threshold, which is just below the point at which damage can occur, we feel.
6:13 Speaker 01 A pinprick or the point at which something that is too warm and it has the risk of burning us.
6:19 Hanne Tidnam? And is that threshold the same for everyone or different for everyone?
6:22 Speaker 01 It's surprisingly similar that if you measure it and in a situation where you remove all the emotional aspects of pain, the threshold at which someone feels something has been warm and then hotter. And then when it switches to actually painful is 42 degrees with a surprisingly small variation.
6:45 Hanne Tidnam? That is surprising. So the idea of being more pain tolerant because of your accumulated experiences or sensitivities, is that not?
6:55 Speaker 01 That is true, but that is not for that kind of pain. If you're drinking your coffee and it's too hot and it burns your tongue, you will stop drinking it immediately. You weren't even aware of it. We've all learned to take a little sip and maybe not even put the coffee in our mouth. So we've been trained by our experience. We try and avoid that pain.
7:15 Hanne Tidnam? Yeah.
7:15 Speaker 01 For that protective pain to work, the pain has to be unpleasant. And in order for it to work, you can't say, I'll deal with it later.
7:22 Hanne Tidnam? Right.
7:23 Speaker 01 You've got to deal with it immediately.
7:25 Hanne Tidnam? Yeah.
7:25 Speaker 01 So it demands our attention and it's intense and it's unpleasant. And in that sense, it is that analogy of a switch. You have switched on something that focuses your attention. I have to do something. I have to avoid this situation immediately. We're talking a matter of seconds.
7:41 Hanne Tidnam? It's actually incredibly effective when you think about it like that, a very effective tool.
7:45 Speaker 01 The protective mechanism of pain requires an intense stimulus to activate it, a noxious stimulus. And we actually call this nociceptive pain, which is the pain that is initiated by a noxious stimuli. Now, the big difference, coming back to our postsurgical pain, we're now no longer dealing with protection from injury because the injury has occurred. It could either occur traumatically if you're involved in a motor vehicle accident, or it could be because you have surgery. In both cases, there's trauma to your tissues. So you no longer need a protective system to prevent tissue damage because you have tissue damage. So what happens there? Instead of protecting you from tissue damage, evolution has developed a system that helps the injury to heal.
8:29 Speaker 01 And how does it do that? It makes the injured part hypersensitive. If you think about an injury or an inflammation, Just touching that wounded side will produce pain. So we've now got a complete shift. The pain is now activated by a stimulus that would normally be innocuous. A sensation that would normally just be light touch. Or, in the case of a bad sunburn, a shower that would normally be pleasantly warm is now burning hot, even though the temperature is not in the hot range.
9:01 Hanne Tidnam? So it's not about the stimulus, it's about the condition?
9:04 Speaker 01 Absolutely. The nervous system has changed. It's become hypersensitive, such that normally innocuous stimuli are now activating the pain system. And we have tenderness, soreness, a heightened sense of pain. This is an adaptive thing. For example, if, after major abdominal surgery, if there were a way to completely eliminate the pain, and you say, "Fine, I'll go for a jog," that would not be a good idea, because you've got this wounded tissue. It needs time for the wound to heal, to repair itself. And, you know, the same with if you've got arthritis, where there's damage to the joint. If you excessively use the joint, if you were pain-free, you would damage that joint.
9:46 Hanne Tidnam? It's still essentially protective in nature.
9:49 Speaker 01 It's not protecting you from the external environment and potential danger to your tissue. It's protecting the injured body part from further injury, allowing repair to occur. And so, funnily enough, the pain that I thought I first wanted to cure, post-operative pain or post-traumatic pain, so you do want to try and reduce it to make people feel comfortable, but at the same time, if you eliminate it, that would be a real problem. But that then leaves our patients, who may not have any surgery, they have no tissue damage, and who have pain that just persists for years and years and years. One of the commonest causes of that is damage to the nervous system itself. And we call that neuropathic pain.
10:32 Speaker 01 And we now appreciate this is no longer telling us about the presence of noxious stimuli or the presence of an injured part. It is the malfunction of the nervous system itself. It is a disease of the nervous system and is mechanistically quite different from either the two other kinds of pain.
10:50 Hanne Tidnam? So there's three major categories of pain now?
10:53 Speaker 01 And there's one fourth, right?
10:54 Hanne Tidnam? Oh, really? Okay.
10:55 Speaker 01 And this is a group of patients who tend, not exclusively, but tend to be women. There's no noxious stimuli, there's no tissue inflammation, there's no damage to the nervous system, but they may have chronic widespread pain. And for a long time, this was labeled as psychosomatic and there was almost a blame feature to that label to the patients. But now we realize they too have an abnormal nervous system. The reason they're feeling pain is because it is if someone has switched up the volume control in their central nervous system such that what would normally be a soft sound
11:37 Speaker 01 is now very loud and for them, a soft touch now produces pain. So this is a pathological functioning of the nervous system in the absence of damage to the nervous system.
11:49 Hanne Tidnam? Is it congenital in those cases?
11:51 Speaker 01 Overall, for most clinical pain conditions, there is actually a very strong heritable component, something like 50% of the risk of developing pain is heritable. We know that from twin studies. So if you look at identical twins, if one of the twins has clinical pain, there's a very high chance that the identical twin will have it. If they're non-identical, it's lower, and if they're not related, then it falls way back. So something like 50% is driven by genetic variances that we get from our parents.
12:27 Hanne Tidnam? You talk about phenotyping pain. That's what you mean essentially now, that we're able to understand which type of pain and therefore treat it, presumably treat it differently.
12:37 Speaker 01 Right.
12:38 Hanne Tidnam? What was behind the scientific breakthroughs that made that possible? Were there technological reasons or just sort of the accumulation over time of understanding? What were the pinnacle moments that shifted things?
12:50 Speaker 01 Technology now does enable us to interrogate the function of the nervous system in a way that wasn't possible. We can see activity using a number of indicators. We can also opt to genetically activate specific parts of the nervous system. It is now possible in preclinical models to genetically target a light sensitive protein into defined sets of neurons. And you can then use a laser light to activate those sets of neurons in a very controlled way.
13:20 Hanne Tidnam? Super precise.
13:21 Speaker 01 Absolutely precise. And you can then dissect out the role of each sets of neurons and particular circuits in a way that just wasn't possible. So this is a very exciting technological breakthrough. And the same thing with recording. We can genetically put calcium sensitive dyes into specific sets of neurons and use little microscopes and from that can see the activity of broad populations of neurons in different circumstances. So this is an extremely exciting time in neuroscience, but these technological breakthroughs are enabling us to dissect out the function of the brain.
13:59 Hanne Tidnam? So what you're saying is essentially with these new tools, we're seeing different areas light up in different ways than we once expected, which categorizes into different types of pain and reaction.
14:11 Speaker 01 Right. The breakthrough came when we realized that acute nociceptive protector pain was different from inflammatory or neuropathic and then what we call dysfunctional pain. There's been a whole set of data looking at the mechanisms that drive each of them. What exactly happens when you have a noxious pinch? Which sets of neurons are activated? How does this environmental mechanical stimulus get converted into electrical activity? Which neurons transmitted? What are the signals that they use to transfer the input from the periphery to the central nervous system? Which parts of the brain do they activate? Which circuits? All of that, we're beginning to dissect out.
14:51 Speaker 01 And as we do that, we're revealing potential points at which there could be therapeutic intervention. I think our greatest understanding now is the protective pain. How it's switched on, which sets of neurons are responsible? Which parts of the spinal cord and brain are involved? We also know that in the presence of inflammation, as part of the tissue injury, there's a massive recruitment of the immune system. These produce signaling molecules that act on the neurons. But there are also changes in the central nervous system as well. As it becomes activated, there are changes such that the transmission of input can be amplified.
15:30 Speaker 01 It can spread so that, yes, at the site of the tissue injury, there's, and as expected, that actually the tissue surrounding it, which is not injured, that is also hypersensitive. And that is a manifestation of the presence in the central nervous system of what we call central sensitization and abnormal amplification.
15:50 Hanne Tidnam? So it's happening both at the same time?
15:51 Speaker 01 There's both peripheral sensitization, where the threshold is reduced, and within the central nervous system, there is an amplification of the signals such that inputs that would normally not be painful now begin to drive pain.
16:06 Hanne Tidnam? So now it begins to seem like our ways of treating pain have been just this huge hammer that we've been hitting all kinds of different things with this giant blunt instrument.
16:17 Speaker 01 Absolutely.
16:18 Hanne Tidnam? So let's talk about the link between pain and addiction. We think about pain as being linked to addiction because of the category of opiates, largely. Can I ask a little bit about the science behind what we understand to be going on there, neurologically speaking? Why those two tend to go hand in hand? Or are we able to pull them apart?
16:41 Speaker 01 The big problem with opioids is that in addition to reducing pain, they produce euphoria. The addiction comes from that euphoric signal, which occurs in the brain, in a different part of the brain from where they act to reduce pain. And so you have two parallel systems. You have pain, and it's a reduction by opioids. And then you have the pleasure centers that are activated by morphine, which gives someone a high. And not everyone has it, but those people who do then initiate a craving behavior. And again, there are certain individuals who have a high risk of craving, who then become dependent and addicted. But analgesia does not mean that there's going to be euphoria.
17:25 Hanne Tidnam? It just so happens in that one-
17:26 Speaker 01 Just so happens in the case of opioids, of which morphine is the typical example, not only does it reduce pain, but it produces the sense of well-being, of euphoria, of happiness. But you don't need to switch that system on to get the pain relief. So in a sense, it's extremely bad luck. The intertwining of pain and addiction now is largely through the fact that through opioid prescription, has until very recently been the means by which people are introduced to opioids. So until literally a few years ago, if you had dental surgery, your dentist would give you 20 oxycodone.
18:09 Hanne Tidnam? Why was it always so much? It always seemed like much more than one would need. Because what a big switch from your post-surgery beds where they, okay, well, pain's just part of it.
18:23 Speaker 01 So basically, this is not the first opioid crisis that we've had. We've, in the 19th century- There was massive addiction, the famous opium wars. So the addictive qualities and the respiratory depression and all the other bad features of opioids have been around since the extract of the poppy was recognized. It was for that reason that in the middle of the 20th century physicians were wary, highly wary of treating their patients with opioids. And that's why on my first exposure, there were patients literally crying in pain because the surgeons of that time-
19:01 Hanne Tidnam? Because of the backlash.
19:02 Speaker 01 Because of the backlash.
19:03 Hanne Tidnam? Oh, how interesting, like a pendulum.
19:05 Speaker 01 So then, then what happened in the, the early eighties, the view came that if you gave a morphine and its equivalent drugs to patients in pain, there was no risk of addiction. This came from, from palliative care because there was in the eighties, a growing recognition that patients with terminal cancer did need very active treatment. And a big part of that clearly is morphine. Those patients do need opioids, most, most of them in their, their late stage of life. And from that very good use, it spread out to say, well, patients who don't have terminal cancer, who have pain, also need opioids.
19:50 Speaker 01 And a belief appeared in the medical profession that if you gave morphine or any other opioid to patients with pain, there was no risk of addiction. That was not based on proper studies and it's turned out to be incorrect. So that led to an enormous expansion in the prescription of opioids.
20:12 Hanne Tidnam? So it wasn't so much that there was any kind of intentional sort of it was just, it was thought not to matter, not to pose a risk.
20:19 Speaker 01 And not to pose a risk. It was done with the best of intentions. So the idea was if you have a patient with pain, give them appropriate treatment. So the prescription opioids were the avenue initially in our current opioid crisis, the means by which people could become introduced to opioids. Although there've been many attempts to try and design drugs that only have analgesia, if they act through the mu opioid receptor. I think in the end, the risks are very high that you will always get the risk of addiction and abuse.
20:53 Hanne Tidnam? But why is the euphoria addictive? I mean, I feel euphoria, you know, over, I don't know, emotional events. And I feel that I can experience it and let it go. What is happening there that that kind of euphoria leads to the uncontrolled craving?
21:12 Speaker 01 If you gave a hundred people morphine, some of them would feel terrible nausea. Some would feel they are floating on a cloud and happy and all their worries had disappeared. And others wouldn't. And that again reflects out the genetic variation. But there are a group of people who, when they are exposed to morphine, feel so pleasant. And on top of it, when the morphine wears off, they feel so terrible that they develop that craving. So it's a combination of the positive feeling they get when they have the morphine and the terrible negative feeling when it wears off.
21:51 Speaker 01 It's actually the strength of the negative feeling that is one of the major drivers of addiction. If you ask addicts, they'll say their first exposure was intensely pleasant and they've never been able to reach that same high again. However, when they stop it, they feel so terrible, worse than they ever did starting off with, that they now just trying to get back to a normal, balanced feeling.
22:19 Hanne Tidnam? Now I sort of understand the confluence of cultural and what you grow up around or how whole of a person you feel you are, right? The psychological and the cultural stuff, it's about the contrast. It's not necessarily the euphoria, but the contrast of the euphoria and the lack then of it.
22:36 Speaker 01 If you have A job that is not satisfying, that if your family situation or your economic situation is dire and all these other features, then if you take a drug that makes you feel happy and then, you know, that that becomes a driver of that.
22:54 Hanne Tidnam? So when you start to get this level of detail and resolution, sort of on understanding the different pathways and the different systems that are being triggered, what do you see going forward for where we intervene? Are there solutions starting to change how we treat the pain as well?
23:11 Speaker 01 Absolutely, and I'm very optimistic. I think we're going to move away from the blunt approach where we see pain as a single box and we throw only the same therapy at it, to now having the means to identify in a patient, what is the drive of their pain? What is their particular set of pathological changes that are causing their pain? And that will suggest what is the most appropriate treatment. And that's called, the phenotype is the total pain presentation in the patient and all its features that will reflect the mechanisms that are driving it. And then we can use that to what we call segmentation. We can, instead of seeing the population as a whole, we can break it down. This is a patient where the pain is entirely periphery.
23:56 Speaker 01 It's been driven by, for example, if you had a thorn in your heel and you didn't remove it, whenever you walked, you'd have pain. But that pain has a definable cause and in fact, all you need to do is remove that thorn and your pain will disappear.
24:14 Hanne Tidnam? Well, then you'll have another kind of pain for a little while.
24:17 Speaker 01 Yeah, absolutely. You can identify the cause and you can target your treatment. What the challenge for us now is to find the equivalent of the thorn. These are changes in the function of the nervous system. But once we can find the mechanisms that are operating and use that to help us choose the most appropriate treatment for the patient. One of the big problems in pain management has been Even those drugs that the FDA has approved, such as pregabalin for treatment of neuropathic pain, the vast majority of patients, literally greater than 50%, do not respond at all. They get no benefit whatsoever.
24:56 Hanne Tidnam? Was the drug chosen because of its lack of side effects like addiction?
25:01 Speaker 01 So the FDA has two choices to make when they are approving a drug. The biggest factor is its safety. So if a drug has no or minimal adverse effects or side effects, that is a very big plus. Then they look for efficacy. You need that in order to get approval and put a label to say, I can use this drug to treat neuropathic pain. But they don't require you to say it'll work in all patients with neuropathic pain. You just need to, the pharmaceutical company just needs to show that it is significantly better than no treatment. And that may mean literally it works in 30%, but what about the 70%? They get no benefit.
25:42 Hanne Tidnam? But in the 30% that it did help, was that a drug that intervened in the pathways in a different way?
25:48 Speaker 01 It's a case of serendipity or empirical observation. Pregabalin was a derivative of an earlier drug called gabapentin. Gabapentin, as its name indicated, was designed to be similar to one of the major inhibitory transmitters in the brain. It was designed in this way to switch off overactivity of neurons in the brain in the case of epilepsy and pain and other similar conditions. But it turned out that it didn't actually act in this way at all. But it did have some analgesic signal. And even after it was marketed and approved by the FDA, it took a long time before it was discovered exactly what that signal was.
26:33 Speaker 01 And even to this day, it's not absolutely clear why activation of those particular targets produces.
26:40 Speaker 01 Analges in some patients and not in others.
26:43 Hanne Tidnam? So how do you even begin to consider new therapeutic approaches when you're at the stage of just sort of mapping? Or do you feel we're past mapping and we're starting to understand other kinds of interventions? What are the modalities of treatment for pain that we're going to start beginning to see?
26:59 Speaker 01 A big part of my career has been trying to identify the mechanisms of pain as a basis for designing a new generation of treatments that would mean that we could make opioids obsolete. The technological advances in biomedicine as a whole have really transformed the way we can approach even something as complicated as pain. We now know much more about the nature of tissue injury and the inflammation that occurs and the signaling molecules that are released and how to block them. We now know much more about the excitability of neurons and how they change and how we can target that. Whose signaling leads to the production of pain may be different from others and that enables us to get selectivity.
27:43 Speaker 01 But we also, as I've indicated, can recognize that in patients who have neuropathic pain, we now know the downstream effects of that damage, what are the pathophysiological changes that have occurred and now can design our treatment to intervene. At the moment, most of that treatment just switches off those changes, so it's symptom control. But in the relatively near future, we will also get disease-modifying treatment where we can recognize that if a surgeon damages a nerve during the surgery, there is a high risk, particularly in those people who have a genetic predisposition for the development of chronic neuropathic pain.
28:24 Speaker 01 And we will be able to say this person is at very high risk, therefore, we can give a treatment that will prevent the evolution of those pathological Processes in the brain that will cause that persistent neuropathic pain.
28:39 Hanne Tidnam? So now you're shifting to kind of prevention model from the very beginning, whereas the almost by definition, pain seemed like there was no possibility for preventative, unless you live in a bubble, right? And that we by nature encounter this. I wanted to ask you something a little bit wacky about pain, which is if these are certain receptors and certain pathways, you have different types and we're beginning to understand what happens in these different systems. Do you believe in our psychological ability to manage pain? Is that a real thing? Ideas around self-hypnosis or meditation or what effect do those have on the brain? Or is it just, are we just telling ourselves stories?
29:17 Speaker 01 In the end, what we feel is the net result of the totality of our brain function. And so if you have pain and you're depressed, those will be additive. If you have pain and you are depressed and this interferes with your sleep, that will increase your pain. So you can get into vicious cycles where your pain gets worse and worse and therefore your mood changes. And therefore interventions such as distractions may not switch off your pain, but can make it bearable. And that certainly is, can be a big feature and should be part of the totality of treatment. We shouldn't just rely on medication. It's generally not enough.
29:58 Speaker 01 One of the breakthroughs over the last decade or so has been the recognition that placebo, we see that as a problem because it makes it difficult when we do clinical trials to identify new treatments. In other words, you give a patient just a sugar pill and they respond well to that. And how are you going to differentiate that from an active compound? But that placebo is not wishful thinking. It is the activation, and we know that from functional imaging, of very specific parts of the brain, which then suppress or reduce the activity of those parts of the brain that generate the sensation of pain.
30:36 Hanne Tidnam? So it is having a biological effect?
30:38 Speaker 01 It is a biological effect. And certainly anything that can switch it on would be, is beneficial. It's more variable, it's more difficult to manage. But interventions such as acupuncture are very good at switching on the placebo.
30:51 Hanne Tidnam? That's fascinating. What you're saying is that that actually could in turn cycle back into how you experience the physical pain, just that in the overall composite of how your brain as a system is behaving.
31:06 Speaker 01 There's been a lot of work in this, trying to identify all these confounders or contributors to pain. And the one that seems strongest is something what we call catastrophization, that this is a definable feature of our makeup, that there are some people who, if they have a problem, make it worse.
31:27 Hanne Tidnam? It's a kind of anxiety, right?
31:28 Speaker 01 It is exactly that. And that definitely is highly correlated with the intensity of pain that people experience. And if you can target that catastrophization, where you can get people to overcome that anxiety, the sense of powerlessness and a lack of ownership of their pain, then that is, again, a very good treatment modality.
31:50 Hanne Tidnam? It's not a magic switch, it's a cycle that you're interrupting.
31:53 Speaker 01 And one needs to see it in the context. It's more useful in the setting if you have daily pain that you can control and suppress and deal with.
32:04 Hanne Tidnam? In the next five years, how does our current framework need to shift in the system again in order to allow this different kind of understanding of pain to have actual effect in the clinic and in the hospital?
32:16 Speaker 01 The greatest challenge for pain is that it is a subjective experience. I can't know your pain, you can't know mine. When I say my pain is nine out of 10 on a 0 to 10 scale, and tomorrow I say it's five out of 10, how accurate do you think that is?
32:33 Hanne Tidnam? There's the smiley faces in the picture, yeah.
32:35 Speaker 01 Exactly. And it's extremely difficult. And what if the patient is a neonatal baby or an adult who has Alzheimer's disease, who cannot report their pain? How do we measure that? So I think a crucial element is we need new, objective ways of surrogates of pain, pain biomarkers. One of the most promising ways, there'll be others for sure, but is to use functional brain imaging to look at the changes in the activity patterns in the brain. This has been around for some time. The signals have been very noisy. But using artificial intelligence as a tool to help us measure pain now, instead of having a human look at the patterns of changes in activity
33:20 Speaker 01 and say, ah, that constitutes the presence of pain, machine learning algorithms that are picking up patterns that we wouldn't even have detected.
33:28 Hanne Tidnam? And correlating them to pain.
33:29 Speaker 01 And correlating. So it is reaching a point now that the signals we can get from those functional images will tell us that there's a very high likelihood that the patient has pain or not pain. That also raises ethical issues because if someone says they have pain and your functional imaging says there's no equivalent, how do you deal with that? But the positive is that we now have tools to go beyond just relying on someone saying, I have very bad pain or I have no pain, to a point at which we can understand the changes that underlie that pain and the associated features. Because not only do you pick up the sensory experience, but you do pick up the changes that reflect the anxiety, the helplessness,
34:13 Speaker 01 the other features that constitute the entire picture that a patient has.
34:18 Hanne Tidnam? And to take it from the realm of purely subjective to objective.
34:23 Speaker 01 Exactly. And that's helping us in our preclinical studies because, again, pain is extremely complex. There are many different features. If we study those neurons that are the prime initiators for pain, and we can actually grow, using stem cell technology, we can take patient's stem cells, we can convert them into neurons, we can look at the features of the function of those neurons. In the past, we used to look at one feature, say, the firing of action potentials as a surrogate for their activity. Now we recognize they are. Tens of features, of phenotypes, as we call it, that constitute the entire functional repertoire of these cells. And again, machine learning is helping us see the patterns
35:06 Speaker 01 and how they correlate with a normal state, a disease state, what kind of disease state, and the response to treatment. So we now have tools at last to embrace complexity and from that define what are the components and which ones are relevant and important and which ones to go for.
35:25 Hanne Tidnam? And where to go next.
35:26 Speaker 01 And where to go next. We are identifying other targets that are looking very promising. And I'm optimistic that in consequence, I think we are going to be able to make choices about which are the best targets to go for, find the means to identify the best modalities to go for those targets, to develop new ways of running clinical trials that will be more sensitive, both to suppress symptoms, but also to prevent the evolution of permanent changes in the function of the nervous system that is a big driver of the chronicity of pain.
36:00 Hanne Tidnam? Do you think that if we are able to get to that stage, it would just roll through the system and become adopted? Or would there be challenges?
36:08 Speaker 01 There are always challenges. As is typical in biotech, there are going to be many failures. I think it is important that we go for risky because some of them will pan out. But the portfolio of potential possibilities is sufficiently exciting now that I do think this is, that we'll be able to look back in the near future and say, at last, we both understand pain and we can now control it in a way that has just simply not been possible before.
36:39 Hanne Tidnam? I feel like we need a new thing in the doctor's office that says you're experiencing one of these four different types of pain.
36:47 Speaker 01 Exactly.
36:47 Hanne Tidnam? For starters. Thank you so much for joining us on the A16Z podcast.
36:51 Speaker 01 It's a pleasure.
Previous 16 Minutes on the News #8: Apple Camera, Services; Wearables - Where are We Next 16 Minutes on the News #9: All the Recent Phone Hacks Page updated September 30, 2026 · transcript and summary are machine-generated